for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
PharmAsia News
   Journal TOC RSS feeds Export to Zotero Follow    
   Full-text available via subscription Subscription journal
     ISSN (Print) 1875-7774
     Published by Informa plc Homepage  [13 journals]
  • Roche CEO Tries To Squelch Chugai Buyout Talk
    • Abstract: Roche CEO Severin Schwan has attempted in an interview to dial back speculation the company had plans to buy the nearly 40% of shares it does not already own in Chugai Pharmaceutical.
      PubDate: Thu, 18 Sep 2014 02:30:02 -040
       
  • Japan Scientists Combine Statins, iPS Cells For Bone Disease
    • Abstract: Japan researchers suggest combining anti-cholesterol statin drugs with a stem cell treatment could aid patients with skeletal dysplasia, a genetic bone disease.
      PubDate: Thu, 18 Sep 2014 02:30:01 -040
       
  • Ranbaxy Nexium Generic Still Not Launched Despite
           Approval
    • Abstract: Five months on, Ranbaxy Laboratories’ generic version of AstraZeneca's best-selling gastrointestinal drug Nexium (esomeprazole) remains off the market during its six months of marketing exclusivity.
      PubDate: Thu, 18 Sep 2014 02:30:00 -040
       
  • JMRF Survey: Over 1,000 Serious Side-Effects From HPV Vaccines
    • Abstract: Of the roughly 2,500 cases of side-effects caused by the cervical cancer vaccines first recommended and then not supported by the Japanese government, 1,112 were found to be severe, according to an independent analysis.
      PubDate: Wed, 17 Sep 2014 22:00:01 -040
       
  • Japan Health Minister Promises iPS Cell Cost Reduction
    • Abstract: Japan’s new health minister Yasuhisa Shiozaki has promised that medical techniques utilizing iPS cells will receive more financial support to reduce costs.
      PubDate: Wed, 17 Sep 2014 21:55:00 -040
       
  • Japan Survey: Many Pharmacies Not Receiving Generic Premiums
    • Abstract: 40% of Japan Pharmacy Association member pharmacies are not eligible for generic drug dispensing system premiums since the requirements for the reimbursements were raised in April.
      PubDate: Wed, 17 Sep 2014 21:50:01 -040
       
  • Taiwan’s ITRI Expands To Biomedical Field, Looks For Japan
           Cooperation
    • Abstract: With aggressive investment by the Taiwanese government in recent years, the Taiwan Industrial Technology Research Institute is showing results in the discovery of new regenerative medicine and biomedical drugs.
      PubDate: Wed, 17 Sep 2014 21:45:01 -040
       
  • JB, Mitsubishi Tanabe To End Plasma Derivatives Deal
    • Abstract: The Japan Blood Products Organization and Mitsubishi Tanabe Pharma have decided to end their sales alliance regarding plasma derivatives at the end of March 2015.
      PubDate: Wed, 17 Sep 2014 21:40:02 -040
       
  • Positive Data But Uphill Struggle For Takeda’s Trelagliptin'
    • Abstract: Takeda has released the first detailed late-stage clinical results for trelagliptin, showing positive data for the once-weekly DPP-4 inhibitor, which is currently awaiting Japanese approval for type 2 diabetes. But a number of factors may play on the drug’s commercial prospects.
      PubDate: Wed, 17 Sep 2014 19:45:04 -040
       
  • First iPS Cell Trial Underway But A Long Way To Go
    • Abstract: Researchers in Japan have "dosed" the initial patient in the world's first clinical trial involving a regenerative therapy based on the country's flagship induced pluripotent stem (iPS) cell technology.
      PubDate: Wed, 17 Sep 2014 19:45:00 -040
       
  • Otsuka Tries To Halt Alkermes Ride On Abilify’s Coattails
    • Abstract: FDA should not review or approve Alkermes’ NDA for aripiprazole lauroxil because it is based on only one adequate and well-controlled clinical trial, Otsuka argues.
      PubDate: Wed, 17 Sep 2014 18:50:03 -040
       
  • Life Pharma To Build $160 Million Worth Of Plants In Abu Dhabi
    • Abstract: Life Pharma, a unit of VPS Healthcare in Abu Dhabi, said it would spend $160 million to build production facilities in a local industrial zone to make generic versions of cancer and other drugs.
      PubDate: Wed, 17 Sep 2014 18:35:05 -040
       
  • U.S. DOJ Seeks Medicaid Pricing Data From Ranbaxy
    • Abstract: Ranbaxy Laboratories has come under the scrutiny of the U.S. Justice Department, which seeks documents and pricing data covering the drugs it supplies under the Medicaid program.
      PubDate: Wed, 17 Sep 2014 18:35:00 -040
       
  • Sun Licenses Global Rights To Psoriasis Drug From Merck
    • Abstract: Sun Pharmaceutical Industries has licensed global development and marketing rights from Merck for its MK3222 (tildrakizumab), a treatment for chronic plaque psoriasis.
      PubDate: Wed, 17 Sep 2014 18:30:01 -040
       
  • Novartis Urges More Transparent Patent Process In China
    • Abstract: The head of intellectual property issues for Novartis Pharma has called for China’s authorities to do more to make the patent system more transparent.
      PubDate: Wed, 17 Sep 2014 02:25:03 -040
       
  • Piramal To Sell Diagnostics Business To DiaSys'
    • Abstract: Piramal Enterprises has agreed to sell its diagnostic solutions business to Germany's DiaSys Diagnostic Systems, according to sources.
      PubDate: Wed, 17 Sep 2014 02:25:00 -040
       
  • China Moves To Close Lag In Stem Cell Technology
    • Abstract: China is adopting various policies that could lead to a boom in research in stem cell technology, according to the head of Guangzhou Saliai Stem Cell Science and Technology.
      PubDate: Wed, 17 Sep 2014 02:15:04 -040
       
  • Emerging Markets Regulatory Tracker: Australia (Vol. 4 No. 59)
    • Abstract: Australia’s Therapeutic Goods Administration has issued amended non-clinical studies guidance needed to register a prescription medication.
      PubDate: Wed, 17 Sep 2014 01:00:01 -040
       
  • ISO Issues Two Traditional Chinese Medicine Standards
    • Abstract: The International Organization for Standardization (ISO) recently and firstly issued two international information standards for traditional Chinese medicines, a “Semantic Network Framework of Traditional Chinese Medicines” and “Literature Meta-data of Traditional Chinese Medicines”.
      PubDate: Tue, 16 Sep 2014 22:15:04 -040
       
  • NHFPC Prohibits Physicians From Unauthorized Remote Medical Services
    • Abstract: The NHFPC recently held a press conference to state that no physicians are allowed to provide remote medical services away from a medical institution, according to the published “Opinions on the Promotion of Remote Medical Services by Medical Institutes”.
      PubDate: Tue, 16 Sep 2014 22:10:00 -040
       
  • Pfizer Starts First Pharma Big Data Platform In China
    • Abstract: Pfizer has announced that its Shanghai Department of Healthcare and Pharmaceuticals officially launched a big data management platform, the first such big data initiative in the Chinese pharmaceutical industry.
      PubDate: Tue, 16 Sep 2014 22:05:03 -040
       
  • Free Prenatal Testing To Roll Out In Beijing
    • Abstract: The Beijing HFPC has announced that free pregnancy tests will be gradually expanded from the rural to urban population, and it aims to cover the whole city next year.
      PubDate: Tue, 16 Sep 2014 22:00:01 -040
       
  • Regulation, Reimbursement Notes From Thailand
    • Abstract: Thailand’s military junta has made few moves to tackle reimbursement reforms since a coup in May. But the appointment of a cabinet this month may signal action on health care spending levels.
      PubDate: Tue, 16 Sep 2014 21:55:05 -040
       
  • Hisun’s Biosimilar Enbrel To Get CFDA Site Inspection
    • Abstract: The China FDA’s website indicates that Hisun Pharma’s “AnBaiNuo”, a biosimilar version of Amgen and Pfizer’s Enbrel (etanercept), will be on-site inspected within this month for drug registration purposes.
      PubDate: Tue, 16 Sep 2014 21:55:01 -040
       
  • United BioPharma To Build $33.2 Million Plant In Taiwan
    • Abstract: United BioPharma said it would build a $33.2 million antibody-production plant a home in Taiwan, expected to be operational by the end of 2016 and making 100 kilograms a year.
      PubDate: Tue, 16 Sep 2014 21:35:05 -040
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014